Handelsbanken Fonder AB / HALO
Handelsbanken Fonder AB’s Halozyme Therapeutics Inc Position
Does Handelsbanken Fonder AB own Halozyme Therapeutics Inc (HALO)? Yes — 493.5K shares worth $32M (+0.11% of its 13F portfolio) as of Q1 2026, down from 591.9K shares the prior filed quarter.
Position Value
$32M
Q1 2026
Shares
493.5K
% of Portfolio
+0.11%
Quarters Held
24
currently held
Position History HALO
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 493.5K | $32M | +0.11% |
| Q4 2025 | 591.9K | $40M | +0.12% |
| Q3 2025 | 388.4K | $28M | +0.09% |
| Q2 2025 | 212.4K | $11M | +0.04% |
| Q1 2025 | 266.1K | $17M | +0.07% |
| Q4 2024 | 516.5K | $25M | +0.09% |
| Q3 2024 | 1.97M | $113M | +0.45% |
| Q2 2024 | 1.11M | $58M | +0.25% |
| Q1 2024 | 828.7K | $34M | +0.15% |
| Q4 2023 | 246.1K | $9M | +0.04% |
| Q3 2023 | 23.9K | $912,000 | +0.01% |
| Q2 2023 | 22.1K | $796,000 | 0.00% |
| Q1 2023 | 272.1K | $10M | +0.06% |
| Q4 2022 | 20.7K | $1M | +0.01% |
| Q3 2022 | 20.7K | $817,000 | +0.01% |
| Q2 2022 | 20.7K | $909,000 | +0.01% |
| Q1 2022 | 23.6K | $940,000 | +0.01% |
| Q4 2021 | 28.5K | $1M | +0.01% |
| Q3 2021 | 28.5K | $1M | +0.01% |
| Q2 2021 | 28.5K | $1M | +0.01% |
| Q1 2021 | 23.5K | $978,000 | +0.01% |
| Q4 2020 | 30.6K | $1M | +0.01% |
| Q3 2020 | 40.8K | $1M | +0.01% |
| Q2 2020 | 81.5K | $2M | +0.01% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Handelsbanken Fonder AB’s full portfolio or all institutional holders of HALO.